首页|Self-assembly drug-albumin nanocomposites for nonalcoholic fatty liver disease treatment
Self-assembly drug-albumin nanocomposites for nonalcoholic fatty liver disease treatment
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
? 2022Nonalcoholic fatty liver disease (NAFLD) is a chronic metabolic liver disease closely related to obesity， which has become a global health problem。 However， current pharmacological therapies for NAFLD are limited by potential side effects， low effectiveness and poor aqueous solubility。 Herein， we designed functionalized drug-albumin nanocomposites (BAM15@BSA NPs)， which were prepared by self-assembly of the anti-obesity small-molecule drug (BAM15) and bovine serum albumin (BSA)， for treatment of NAFLD。 The proposed BAM15@BSA NPs not only improve aqueous solubility and half-life of BAM15 but also exhibit hepatic-targeted capacity and an increased therapeutic efficacy。 In vitro experiments revealed that BAM15@BSA NPs possessed excellent biocompatibility， and improved resistance to adipogenesis and reduced lipid accumulation in human hepatocellular carcinoma cells。 In vivo， BAM15@BSA NPs showed liver targeting ability and powerful anti-obesity effects without altering body temperature or affecting food intake， and could effectively alleviate hepatic steatosis and improve therapeutic efficacy for NAFLD treatment。 The above findings demonstrated that BAM15@BSA NPs potentially served as a safe and effective drug for NAFLD treatment。
Chongqing Key Laboratory for Pharmaceutical Metabolism Research Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center College of Pharmacy Chongqing Medical University
NSTL
Elsevier
